Physician profile
Stacy Royer
NPI 1053911149
$5,054.37
in general payments reported to CMS, 2019-2025
32 companies · $1,437 in 2025
The $1,437 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $390 · 2022: $607 · 2023: $1,247 · 2024: $1,373 · 2025: $1,437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,058.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,057.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $743.25 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $593.41 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $517.01 | 2023-2025 | |
| Lilly USA, LLC | $439.47 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $431.11 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $410.49 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $283.79 | 2022-2025 | Jardiance, Synjardy |
| Bausch Health US, LLC | $201.25 | 2022-2025 | Aplenzin, Wellbutrin |
| Exact Sciences Corporation | $150.78 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $134.59 | 2022-2025 | Repatha, Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $133.45 | 2022-2024 | |
| Dexcom, INC. | $123.95 | 2024-2025 | Dexcom G6 Transmitter |
| Eisai INC. | $113.65 | 2021 | |
| Cmp Pharma, INC. | $83.78 | 2022 | |
| Noven Therapeutics, LLC | $83.44 | 2024 | Xelstrym |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $79.84 | 2023-2024 | Xarelto |
| Medtronic, INC. | $70.04 | 2024-2025 | Synchromedii, Intellis Adaptivestim |
| Xeris Pharmaceuticals, INC. | $61.90 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $55.34 | 2022-2023 | Xifaxan |
| Currax Pharmaceuticals LLC | $44.78 | 2022-2023 | Contrave, Nexlizet, Nexletol |
| Astellas Pharma US INC | $44.33 | 2024 | Veozah |
| Amarin Pharma, INC. | $37.61 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $36.07 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $33.83 | 2022 | |
| Merck Sharp & Dohme LLC | $32.63 | 2024 | Gardasil 9, Gardasil, Capvaxive |
| Novartis Pharmaceuticals Corporation | $24.18 | 2023 | |
| Cranial Technologies, INC | $20.53 | 2023 | Doc Band |
| Tolmar, INC. | $15.99 | 2025 | Jatenzo |
| Esperion Therapeutics, INC. | $15.79 | 2023 | Nexletol |
| Si-Bone, INC. | $15.46 | 2021 | |
| Irhythm Technologies, INC. | $12.70 | 2023 | Zio Xt Patch |
| Genentech USA, INC. | $9.93 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacy Royer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.